Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer.
about
Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinomaIdentification of a three-gene expression signature of poor-prognosis breast carcinomaVandetanib as a potential new treatment for estrogen receptor-negative breast cancers.Arpin downregulation in breast cancer is associated with poor prognosis.Clinical relevance of tumor cells with stem-like properties in pediatric brain tumors.Similar NF-κB gene signatures in TNF-α treated human endothelial cells and breast tumor biopsies.Quantitative real-time RT-PCR and chromogenic in situ hybridization: precise methods to detect HER-2 status in breast carcinomaPIK3R1 underexpression is an independent prognostic marker in breast cancer.Single agent and combination studies of pralatrexate and molecular correlates of sensitivity.Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate bindingProtein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patientsATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels.The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer.The Possible Impact of Obesity on Androgen, Progesterone and Estrogen Receptors (ERα and ERβ) Gene Expression in Breast Cancer Patients.In-silico identification and functional validation of allele-dependent AR enhancers.Loss of ERbeta expression as a common step in estrogen-dependent tumor progressionIdentification of new candidate therapeutic target genes in triple-negative breast cancerEstrogen receptor α regulates non-canonical autophagy that provides stress resistance to neuroblastoma and breast cancer cells and involves BAG3 functionPIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups.Prognostic value of maspin mRNA expression in ER alpha-positive postmenopausal breast carcinomasPredictive factors of sensitivity to elisidepsin, a novel Kahalalide F-derived marine compoundEstrogen receptor (ER) beta or p53 attenuates ERalpha-mediated transcriptional activation on the BRCA2 promoter.Prognostic value of a newly identified MALAT1 alternatively spliced transcript in breast cancer.Co-transcriptional R-loops are the main cause of estrogen-induced DNA damage.Sex hormone receptor repertoire in breast cancer.Biopathological Significance of TLR9 Expression in Cancer Cells and Tumor Microenvironment Across Invasive Breast Carcinomas Subtypes.Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.Mutations and polymorphisms of estrogens receptors genes and diseases susceptibility.ERα and ERβ co-expression: An indicator of aggressive tumors and hormonal sensitivity.Unraveling the Role of Huntingtin in Breast Cancer Metastasis.TPD52 represents a survival factor in ERBB2-amplified breast cancer cells.CAG repeat size in Huntingtin alleles is associated with cancer prognosis.Prognostic value of ERBB family mRNA expression in breast carcinomas.Effects of estrogen on collagen synthesis by cultured human osteoblasts depend on the rate of cellular differentiation.Non-competitive steroid inhibition of oestrogen receptor functions.Variations in the mRNA expression of poly(ADP-ribose) polymerases, poly(ADP-ribose) glycohydrolase and ADP-ribosylhydrolase 3 in breast tumors and impact on clinical outcome.Evidence for functional estrogen receptors alpha and beta in human adipose cells: regional specificities and regulation by estrogens.Immunohistochemical expression of estrogen receptor beta in normal and tumoral canine mammary glands.Involvement of the FOXO6 transcriptional factor in breast carcinogenesis.Quantification of PKC family genes in sporadic breast cancer by qRT-PCR: evidence that PKCι/λ overexpression is an independent prognostic factor.
P2860
Q24795015-8FE80D69-D27A-4F09-A82F-CFE7E5882D12Q24802692-D8FF8C72-CA69-4AF6-B2B6-0E64CAE34E54Q27853297-06821A08-5363-4913-A19E-8A9153BDD3EFQ30724719-583EA605-48E6-4514-9044-FA034DB6F1BDQ30997872-87F997B3-388F-4C3A-9B20-54224DCDF6A0Q31022986-A8CE9B8E-FA19-4E45-BF34-F4F38D7321F2Q33421127-8AC27D7F-7121-40B7-8CCB-906DB49C9155Q34478129-6121D993-416D-4B26-9640-6309A016352DQ34543815-D827BFDF-428E-454B-BE63-FA218FF456C9Q34564173-12978512-0484-42E4-A72A-37E8AF77FF6AQ34998421-31F36E6B-EB92-486F-8B4B-9E7E22D52504Q35198369-E1E57DCB-780F-4847-8FD4-AF4CFCC734AAQ35587582-BEEEAE30-B9FE-43AA-9882-FCC0768DBC9CQ35607776-D45565AA-B82C-45C5-A972-B100E02F181EQ35741562-A3FC3B31-4515-4F39-8B60-D81E719D4B90Q35888377-82EB217F-F949-457E-A97D-D8AF5E34D3C2Q36153325-3C9E80CE-C08B-481A-989A-0EA487F42494Q36293853-04641BAE-9C08-4767-9966-91C120858014Q36393206-E41C0649-E93E-4AE7-9D72-D2D95610E947Q36648801-DF5CE0AC-BC67-4CB0-A405-18950E102EEFQ36994186-6092DCAA-F2E8-4BD7-BEA6-DF0E64877AEDQ37142529-8F1ACFEA-0783-4022-8C48-1CA066D59069Q37174025-3545BFBF-E454-4EA6-A61B-E20B423FD3DAQ37270352-7434BBE9-F649-48BC-B2DF-9E2D247FA4A7Q37353645-52FBEA32-CF05-4550-B43E-5D622088F086Q37605221-E2C91CE4-D904-443B-AAAE-D527588E90FCQ37709099-C7D3FED4-C6D6-4C7B-9DD8-1D98479F21AEQ38063566-25CE6E31-28AB-4614-8857-08D37B203961Q38624809-0F1877ED-BED0-48FF-991D-A60B34F743E0Q38842190-4062F31C-08E4-4F36-84CF-58682C238C05Q39153926-88140A2D-8CB7-4F0B-A66E-71ED9C6947B5Q39918359-24120982-C96F-4CB5-A930-A98C33C2B86EQ43461671-324AB098-6FAC-4442-9F99-53D18C5364F0Q44059983-942D158E-33A2-4949-AD11-1AEF1A6DBDEFQ44124083-C946B00E-8C3F-4692-A0A0-4A3612439DABQ44542715-D12292F2-94D6-449A-8BE3-56AAB3980106Q44755136-89792AC8-3B32-4BA5-8F37-F7B30B302E5AQ44888248-5A3FDDDE-2CD1-477A-8849-9C3075AB9F8DQ50350755-9FC9E477-86C4-4E30-AB08-B5B52FB5D1AAQ54314273-3C566225-5E63-4CB9-BC08-D06BD67B7C19
P2860
Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer.
@en
Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer.
@nl
type
label
Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer.
@en
Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer.
@nl
prefLabel
Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer.
@en
Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer.
@nl
P2093
P2860
P356
P1433
P1476
Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.ONC.1204917
P407
P50
P577
2001-12-01T00:00:00Z
P5875
P6179
1044769391